Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aeglea Biotherapeutics, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Aeglea Biotherapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Aeglea Biotherapeutics, Inc. since 2005.
The reporting company's ticker symbol is AGLE. The reporting company's CIK number is 1636282.
The total value of stock buying since 2005 is $8,974,348.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $83,052.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2018-02-15||Quinn Anthony G. (Interim CEO)||Option Ex||15,211||5.46||83,052|
|2017-12-08||Quinn Anthony G. (Interim CEO)||Buy||600||5.07||3,039|
|2017-12-07||Quinn Anthony G. (Interim CEO)||Buy||2,800||4.99||13,966|
|2017-12-06||Quinn Anthony G. (Interim CEO)||Buy||4,888||4.92||24,073|
|2017-12-05||York Charles N Ii (Chief Financial Officer and VP)||Buy||10,241||4.75||48,695|
|2017-12-05||Quinn Anthony G.||Buy||5,065||4.93||24,975|
|2017-12-04||York Charles N Ii (Chief Financial Officer and VP)||Buy||3,259||4.97||16,197|
|2017-12-04||Quinn Anthony G.||Buy||7,956||4.98||39,620|
|2017-12-01||York Charles N Ii (Chief Financial Officer and VP)||Buy||6,500||4.59||29,854|
|2017-12-01||Quinn Anthony G.||Buy||4,100||4.53||18,577|
|2017-08-15||York Charles N Ii (Chief Financial Officer and VP)||Buy||1,959||2.52||4,928|
|2017-02-21||Isaly Samuel D||Buy||7,000||5.36||37,520|
|2017-02-17||Isaly Samuel D||Buy||71,800||5.19||372,642|
|2017-02-16||Isaly Samuel D||Buy||30,500||5.04||153,720|
|2017-02-15||York Charles N Ii (Chief Financial Officer and VP)||Buy||2,000||4.28||8,568|
|2016-08-15||York Charles N Ii (Chief Financial Officer and VP)||Buy||2,000||3.99||7,974|
|2016-04-12||Cox Russell J.||Buy||7,000||10.00||70,000|
|2016-04-12||Lilly Eli & Co||Buy||500,000||10.00||5,000,000|
Insider trading activities including stock purchases, stock sales, and option exercises of AGLE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Aeglea Biotherapeutics, Inc. (symbol AGLE, CIK number 1636282) see the Securities and Exchange Commission (SEC) website.